Peritoneal carcinomatosis represents end stage disease in many types of cancer, and the majority of patients with carcinomatosis will die from their disease within 6 months. Platinum-based systemic chemotherapy may prolong survival in selected patients, but poor performance status, low response rates, and treatment toxicity have led to conservative (nihilistic) treatment strategies in these patients. However, patients with peritoneal carcinomatosis who are in good condition and with a remaining life expectancy of more than a few months, may still have an unmet need for additional treatment in order to be able to perform with a high quality of life for as long as possible. These patients have often tried several lines of SC with disappointing results, and alternative and more effective treatment strategies are desperately needed.
PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) is a minimal invasive administration of aerosolized chemotherapy within the abdominal cavity, where the laws of physics allow a high tissue concentrations of chemotherapy, but without the usual side effects and toxicity of systemic chemotherapy. Preliminary clinical data suggest a significant efficacy of PIPAC in platinum-resistant peritoneal carcinomatosis, with a confirmed low adverse events profile and with no occupational health safety problems.
This could indicate treatment progress in a difficult palliative situation, but perhaps PIPAC may also challenge the present treatment strategies in cancer patients who have not reached end stage disease, yet.
In close collaboration with the inventors of the PIPAC procedure we are pleased to invite you to the first Scandinavian PIPAC Meeting. The goal of this meeting is to provide a detailed overview of the present research, indications and results related to the PIPAC procedure in patients with peritoneal carcinomatosis.
On behalf of the Organizing Committee we look forward to welcoming you in Odense in 2017.